PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Dec 13, 2019
SOUTH PLAINFIELD, N.J. , Dec. 13, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 9, 2019 it approved non-statutory stock options to purchase an aggregate of 59,150 shares of its common stock to 17 new employees.
Additional Formats
Nov 29, 2019
SOUTH PLAINFIELD, N.J. , Nov. 29, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on November 25, 2019 it approved non-statutory stock options to purchase an aggregate of 144,550 shares of its common stock to 36 new employees.
Additional Formats
Nov 25, 2019
- PDUFA date set for May 24, 2020- - NDA filing is based on data in a broad SMA population of Type 1, 2 and 3 patients- - FDA filing triggers $15M milestone payment to PTC from Roche- SOUTH PLAINFIELD, N.J. , Nov. 25, 2019 /PRNewswire/ --   PTC Therapeutics, Inc.
Additional Formats
Nov 19, 2019
SOUTH PLAINFIELD, N.J. , Nov. 19, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will participate in a panel discussion titled, "Gene Therapy with Base Business – Extracting Value," at the 2 nd Annual Evercore ISI HealthCONx Conference on Tuesday,
Additional Formats
Nov 18, 2019
- AADC deficiency patients are often misdiagnosed as having other neurological conditions such as cerebral palsy - SOUTH PLAINFIELD, N.J. , Nov. 18, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of a no-cost testing program for aromatic L-amino acid
Additional Formats
Nov 11, 2019
- Study meets primary endpoint for patients living with type 2/3 SMA - - Risdiplam has been well tolerated and there have been no drug-related safety findings leading to withdrawal from the study - SOUTH PLAINFIELD, N.J. , Nov. 11, 2019 /PRNewswire/ --   PTC Therapeutics, Inc.
Additional Formats
Oct 31, 2019
SOUTH PLAINFIELD, N.J. , Oct. 31, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on October 25, 2019 it approved non-statutory stock options to purchase an aggregate of 339,875 shares of its common stock to 27 new employees.
Additional Formats
Oct 29, 2019
Tegsedi® approved in Brazil & PTC is prepared for launch PTC completed financing with net proceeds of approximately $376 million SOUTH PLAINFIELD, N.J. , Oct. 29, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the
Additional Formats
Oct 24, 2019
- Results represent 5 year follow up - SOUTH PLAINFIELD, N.J. , Oct. 24, 2019 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new results from its investigational gene therapy, PTC-AADC, in patients living with aromatic L-amino acid decarboxylase (AADC) deficiency.
Additional Formats
Oct 23, 2019
SOUTH PLAINFIELD, N.J. , Oct. 23, 2019 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on October 18, 2019 it approved non-statutory stock options to purchase an aggregate of 144,150 shares of its common stock to 29 new employees.
Additional Formats